Aprea Therapeutics, Inc. (APRE)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Biotechnology (Startups)	1.50M	583.23K
Biotechnology (Startups) Growth	157.63%	-
Total	1.50M	583.23K
Total Growth	157.63%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
United States	1.50M	583.23K
United States Growth	157.63%	-
Total	1.50M	583.23K
Total Growth	157.63%	-

Source: S&P Global Market Intelligence.